PART I [Unaudited Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201.%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Guardant Health's unaudited financial statements for H1 2025 show a 26% revenue increase, a narrowed net loss, and a widening stockholders' deficit [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to **$1.33 billion** as of June 30, 2025, with liabilities slightly up and stockholders' deficit widening to **$305.5 million** Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $629,143 | $525,540 | | Short-term marketable debt securities | $0 | $314,438 | | Total current assets | $883,432 | $1,055,114 | | Total Assets | $1,331,999 | $1,485,609 | | **Liabilities & Stockholders' Deficit** | | | | Total current liabilities | $238,430 | $225,583 | | Convertible senior notes, net | $1,115,526 | $1,142,547 | | Total Liabilities | $1,637,474 | $1,625,256 | | Total Stockholders' Deficit | $(305,475) | $(139,647) | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q2 2025 revenue grew **31%** to **$232.1 million** with a net loss of **$99.9 million**, while H1 2025 revenue increased **26%** to **$435.6 million** with a narrowed net loss Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $232,088 | $177,235 | $435,559 | $345,726 | | Loss from operations | $(106,413) | $(100,618) | $(217,454) | $(200,301) | | Net loss | $(99,899) | $(102,628) | $(195,058) | $(217,613) | | Net loss per share | $(0.80) | $(0.84) | $(1.57) | $(1.78) | - Operating expenses increased across all categories, with sales and marketing showing the largest percentage increase (**46% YoY** for the quarter) to support the Shield product launch[15](index=15&type=chunk)[199](index=199&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities improved to **$123.0 million** for H1 2025, with investing activities providing **$292.2 million**, resulting in a **$105.7 million** increase in total cash Cash Flow Summary for Six Months Ended June 30 (in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(122,974) | $(124,286) | | Net cash provided by investing activities | $292,215 | $22,989 | | Net cash (used in) provided by financing activities | $(65,226) | $4,824 | | Net increase (decrease) in cash | $105,725 | $(98,448) | - Financing activities in H1 2025 included a **$45.0 million** repurchase of treasury stock and **$12.3 million** in debt issuance costs, which were not present in H1 2024[28](index=28&type=chunk)[229](index=229&type=chunk) [Notes to the Unaudited Condensed Consolidated Financial Statements](index=10&type=section&id=Notes%20to%20the%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Key notes detail the FDA approval and launch of the Shield blood test, a **$659.3 million** note exchange yielding a **$13.7 million** gain, and ongoing significant legal proceedings - The Shield blood test for colorectal cancer screening received FDA approval in **July 2024**, became commercially available in **August 2024**, and was included in NCCN screening guidelines in **June 2025**[32](index=32&type=chunk) Revenue Disaggregation (in thousands) | Revenue Source | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Oncology | $158,685 | $130,269 | $309,244 | $256,017 | | Biopharma and data | $56,020 | $43,933 | $101,396 | $81,520 | | Screening | $14,814 | $0 | $20,491 | $0 | | Licensing and other | $2,569 | $3,033 | $4,428 | $8,189 | | **Total revenue** | **$232,088** | **$177,235** | **$435,559** | **$345,726** | - In February 2025, the company exchanged **$659.3 million** of its 2027 Notes for **$600.0 million** of new 1.25% Convertible Senior Notes due 2031, recognizing a **$13.7 million** gain on extinguishment[99](index=99&type=chunk) - A jury awarded the company **$292.5 million** (affirmed at **$287.0 million**) in its false advertising lawsuit against Natera. The company is also defending against patent infringement claims from TwinStrand, Tempus, and CSHL[122](index=122&type=chunk)[123](index=123&type=chunk)[126](index=126&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=35&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q2 2025 financial performance, noting a **31%** revenue increase to **$232.1 million**, rising operating expenses, a **$99.9 million** net loss, and sufficient liquidity for over 12 months [Results of Operations](index=41&type=section&id=Results%20of%20Operations) Q2 2025 total revenue increased **31%** to **$232.1 million**, driven by growth across all segments, while operating expenses rose **22%**, and H1 2025 net loss narrowed due to a debt extinguishment gain Quarterly Revenue Comparison (in thousands) | Revenue Source | Q2 2025 | Q2 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Oncology | $158,685 | $130,269 | $28,416 | 22% | | Biopharma and data | $56,020 | $43,933 | $12,087 | 28% | | Screening | $14,814 | $0 | $14,814 | N/A | | **Total revenue** | **$232,088** | **$177,235** | **$54,853** | **31%** | - Oncology test volume increased to approximately **64,000** in Q2 2025 from **49,400** in Q2 2024[194](index=194&type=chunk) Quarterly Operating Expense Comparison (in thousands) | Expense Category | Q2 2025 | Q2 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Cost of revenue | $81,205 | $72,421 | $8,784 | 12% | | Research and development | $87,449 | $83,102 | $4,347 | 5% | | Sales and marketing | $119,588 | $81,867 | $37,721 | 46% | | General and administrative | $50,259 | $40,463 | $9,796 | 24% | - Other income (expense), net, was a **$7.8 million** income for H1 2025, primarily due to a **$13.7 million** gain on debt extinguishment, compared to a **$44.3 million** expense in H1 2024 which was driven by unrealized losses on an equity investment[217](index=217&type=chunk) [Liquidity and Capital Resources](index=47&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company held **$735.5 million** in cash, with management deeming it sufficient for over 12 months of operations despite a **$2.8 billion** accumulated deficit - The company has an accumulated deficit of **$2.8 billion** as of June 30, 2025[219](index=219&type=chunk) - Cash, cash equivalents and restricted cash totaled **$735.5 million** as of June 30, 2025[220](index=220&type=chunk) - In August 2024, the company established an at-the-market (ATM) offering program to sell up to **$400.0 million** of common stock, but no shares have been sold as of June 30, 2025[223](index=223&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=49&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks from interest rate changes on its **$735.5 million** portfolio and foreign currency fluctuations, though management deems their impact immaterial - Primary market risks are interest rate risk on its **$735.5 million** cash and investment portfolio and foreign currency risk from international expansion[235](index=235&type=chunk)[236](index=236&type=chunk) - A hypothetical **100 basis point** change in interest rates would have an immaterial impact on the fair value of investments[235](index=235&type=chunk) [Controls and Procedures](index=49&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal control over financial reporting - The Co-CEOs and CFO concluded that disclosure controls and procedures were effective as of June 30, 2025[237](index=237&type=chunk) - No material changes in internal control over financial reporting occurred during the quarter[238](index=238&type=chunk) PART II – OTHER INFORMATION [Legal Proceedings](index=51&type=section&id=Item%201.%20Legal%20Proceedings) This section incorporates by reference detailed legal proceedings from Note 8, including ongoing patent litigation and a significant false advertising verdict - Information regarding legal proceedings is incorporated by reference from Note 8 to the condensed consolidated financial statements[240](index=240&type=chunk) [Risk Factors](index=51&type=section&id=Item%201A.%20Risk%20Factors) No material changes occurred to the company's previously disclosed risk factors during Q2 2025, with investors referred to the Annual Report on Form 10-K - There were no material changes to the company's previously disclosed risk factors during the second quarter of fiscal 2025[241](index=241&type=chunk) [Other Information](index=51&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 trading arrangements during the quarter ended June 30, 2025 - No directors or officers adopted or terminated a Rule 10b5-1 trading arrangement during the quarter ended June 30, 2025[246](index=246&type=chunk)

Financial Performance - Total revenue for Q2 2025 reached $232.1 million, a 31% increase compared to $177.2 million in Q2 2024[7, 40] - Oncology revenue grew by 22% year-over-year, reaching $158.7 million in Q2 2025, up from $130.3 million in Q2 2024[10, 40] - Biopharma & Data revenue experienced a 28% year-over-year growth, totaling $56 million in Q2 2025 compared to $44 million in Q2 2024[7, 29, 40] - Screening revenue for Q2 2025 was $14.8 million[7, 32, 40] - The company is raising revenue guidance for the full year 2025 to $915 million - $925 million, representing a 24%-25% year-over-year growth[48] Oncology Business - Oncology volume grew by 30% year-over-year[10] - Guardant360 Tissue ASP increased to approximately $2,000, achieving the company's 2028 target ahead of schedule[12] - Reveal identified that 63% of patients with detectable ctDNA experienced recurrence within three years, compared to 15% of those without detectable ctDNA[25] Screening Business - Shield's Q2 2025 revenue reached $15 million[32] - Shield volume in Q2 2025 was 16,000[32] - Shield non-GAAP gross margin improved significantly, reaching 48% in Q1 2025 and 18% in Q4 2024, and 2% in Q2 2025[42]

[Overview and Key Highlights](index=1&type=section&id=Overview%20and%20Key%20Highlights) Guardant Health reported strong Q2 2025 results with 31% revenue growth, raising full-year guidance and achieving key operational milestones - The company raised its 2025 revenue guidance to a range of **$915 million to $925 million**, representing **24% to 25%** annual growth[1](index=1&type=chunk) - Co-CEO Helmy Eltoukhy highlighted that Guardant360 Liquid's year-over-year growth accelerated for the fourth consecutive quarter, bolstered by the introduction of 11 new Smart Liquid Biopsy applications[3](index=3&type=chunk) - Co-CEO AmirAli Talasaz noted that the Shield screening test showed strong demand, with volume, revenue, and gross profit exceeding expectations in its third full quarter post-launch[3](index=3&type=chunk) - Significant operational milestones include the Shield test's inclusion in NCCN colorectal cancer screening guidelines and the Shield Multi-Cancer Detection (MCD) test receiving FDA Breakthrough Device Designation[5](index=5&type=chunk) [Q2 2025 Financial Performance](index=1&type=section&id=Q2%202025%20Financial%20Performance) Q2 2025 saw 31% revenue growth to $232.1 million, improved gross margins, and reduced net losses, with better free cash flow Q2 2025 Key Financial Metrics (vs. Q2 2024) | Financial Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $232.1M | $177.2M | +31% | | Gross Profit (GAAP) | $150.9M | $104.8M | +44% | | Gross Margin (GAAP) | 65% | 59% | +6 p.p. | | Non-GAAP Gross Margin | 66% | 60% | +6 p.p. | | Net Loss (GAAP) | $(99.9)M | $(102.6)M | Improved | | Net Loss per Share (GAAP) | $(0.80) | $(0.84) | Improved | | Non-GAAP Net Loss | $(55.0)M | $(58.5)M | Improved | | Adjusted EBITDA | $(51.9)M | $(61.9)M | Improved | | Free Cash Flow | $(65.9)M | $(99.1)M | Improved | - Operating expenses increased to **$257.3 million** from **$205.4 million** year-over-year, primarily due to commercial team expansion and marketing activities for the Shield product launch[8](index=8&type=chunk) - As of June 30, 2025, the company had cash, cash equivalents, and restricted cash totaling **$735.5 million**[11](index=11&type=chunk) [Business Segment Performance](index=1&type=section&id=Business%20Segment%20Performance) All business segments showed strong Q2 2025 growth, with Oncology revenue up 22%, Screening generating $14.8 million, and Biopharma & Data up 28% Q2 2025 Revenue by Segment (vs. Q2 2024) | Segment | Q2 2025 Revenue | Q2 2024 Revenue | YoY Growth | | :--- | :--- | :--- | :--- | | Oncology | $158.7M | $130.3M | +22% | | Screening | $14.8M | $0 | N/A | | Biopharma & Data | $56.0M | $43.9M | +28% | | Licensing and other | $2.6M | $3.0M | -13% | | **Total Revenue** | **$232.1M** | **$177.2M** | **+31%** | - Oncology test volume (Guardant360 Liquid & Tissue, Reveal, Response) grew **30%** over the prior year period, reaching approximately **64,000** tests[4](index=4&type=chunk)[5](index=5&type=chunk) - The Screening segment, in its third full quarter of commercial launch, generated **$14.8 million** from approximately **16,000** Shield tests[4](index=4&type=chunk)[5](index=5&type=chunk) [Updated 2025 Full-Year Guidance](index=3&type=section&id=Updated%202025%20Full-Year%20Guidance) Guardant Health significantly raised its full-year 2025 revenue guidance to $915-$925 million and improved non-GAAP gross margin forecasts Full-Year 2025 Guidance Update | Metric | New 2025 Guidance | Prior 2025 Guidance | | :--- | :--- | :--- | | Total Revenue | $915M - $925M | $880M - $890M | | Non-GAAP Gross Margin | 63% - 64% | 62% - 63% | | Non-GAAP OpEx | $840M - $850M | $830M - $840M | | Free Cash Flow Burn | $225M - $235M | Unchanged | Full-Year 2025 Revenue Guidance by Segment | Segment | New 2025 Guidance | Prior 2025 Guidance | | :--- | :--- | :--- | | Oncology Revenue Growth | ~20% | ~18% | | Screening Revenue | $55M - $60M | $40M - $45M | | Biopharma & Data Growth | Mid-teens | Low double-digits | - The company continues to expect the business, excluding the Screening segment, to achieve free cash flow breakeven in the fourth quarter of 2025[12](index=12&type=chunk) [Financial Statements and Reconciliations](index=4&type=section&id=Financial%20Statements%20and%20Reconciliations) This section presents unaudited Q2 2025 financial statements, including statements of operations, balance sheets, and GAAP to non-GAAP reconciliations [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q2 2025 statements show revenue of $232.1 million, an operating loss of $106.4 million, and a net loss of $99.9 million Condensed Consolidated Statements of Operations (in thousands) | Line Item | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | | :--- | :--- | :--- | | Revenue | $232,088 | $177,235 | | Cost of revenue | $81,205 | $72,421 | | Loss from operations | $(106,413) | $(100,618) | | Net loss | $(99,899) | $(102,628) | | Net loss per share | $(0.80) | $(0.84) | [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets were $1.33 billion, with $629.1 million in cash and $1.64 billion in total liabilities Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $629,143 | $525,540 | | Total Assets | $1,331,999 | $1,485,609 | | Total Liabilities | $1,637,474 | $1,625,256 | | Total Stockholders' Deficit | $(305,475) | $(139,647) | [Supplemental Revenue Information](index=7&type=section&id=Supplemental%20Revenue%20Information) This section details Q2 2025 revenue by source, with Oncology contributing $158.7 million and Screening $14.8 million Revenue by Source - Three Months Ended June 30 (in thousands) | Source | 2025 | 2024 | | :--- | :--- | :--- | | Oncology | $158,685 | $130,269 | | Biopharma and data | $56,020 | $43,933 | | Screening | $14,814 | — | | Licensing and other | $2,569 | $3,033 | | **Total revenue** | **$232,088** | **$177,235** | [Reconciliation of GAAP to Non-GAAP Measures](index=7&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Measures) This section reconciles GAAP net loss to non-GAAP net loss and Adjusted EBITDA, adjusting for non-cash items Reconciliation of GAAP Net Loss to Non-GAAP Net Loss (Q2, in thousands) | Description | 2025 | 2024 | | :--- | :--- | :--- | | GAAP net loss | $(99,899) | $(102,628) | | Stock-based compensation | $43,602 | $27,725 | | Unrealized losses on securities | — | $15,485 | | Other adjustments | $1,293 | $962 | | **Non-GAAP net loss** | **$(55,004)** | **$(58,456)** | Reconciliation of GAAP Net Loss to Adjusted EBITDA (Q2, in thousands) | Description | 2025 | 2024 | | :--- | :--- | :--- | | GAAP net loss | $(99,899) | $(102,628) | | Adjustments (Net Interest, Taxes, D&A, etc.) | $48,007 | $40,768 | | **Adjusted EBITDA** | **$(51,892)** | **$(61,860)** |

Core Insights - Tempus AI is experiencing strong operational momentum with significant revenue and gross profit growth, transitioning from a high-growth startup to a scalable enterprise AI and diagnostics company [1][2] Revenue and Profit Growth - In Q4 2024, Tempus AI reported a 35.8% year-over-year revenue growth and a 49.7% increase in gross profit, primarily driven by its high-margin Data and Services segment [2] - For Q1 2025, revenues grew by 34% and gross profit increased by 45%, with gross margin rising from 42.5% to 44.5% [2][7] - The improvements were attributed to lab efficiencies, increased adoption of AI tools like Tempus One and xM, and a higher mix of data services [2][7] Future Earnings Expectations - The upcoming Q2 2025 earnings release is anticipated to show further margin expansion and sequential gains in adjusted EBITDA, supported by new offerings such as Tempus One in EHR systems and the xM liquid biopsy assay [3] - Any upward revision to guidance or increase in contract value, especially from large enterprise deals, could enhance the momentum observed in early 2025 [3] Competitive Landscape - Tempus AI's peers, such as Guardant Health and Natera, are also making significant advancements in AI-driven diagnostics, with Guardant Health introducing new assays and Natera expanding its market reach [6][8] - Natera reported a 36.5% revenue growth in Q1 2025, with gross margin expansion to 63.1%, indicating a competitive environment in personalized oncology [8] Earnings Estimates - The Zacks Consensus Estimate for Tempus AI's 2025 earnings suggests a 56.3% year-over-year improvement [9] - Current estimates indicate a potential for significant growth in earnings per share, with a year-over-year growth estimate of 63.49% for the current quarter [10] Valuation Metrics - Tempus AI currently trades at a forward Price-to-Sales (P/S) ratio of 7.52X, which is higher than the industry average of 5.8X, indicating a potentially expensive valuation [11]

Financial Data and Key Metrics Changes - The company reported that proxies for more than 105 million shares of common stock were received, representing approximately 85% of the total outstanding shares as of the record date [10] - The voting results indicated that all director nominees received a majority of the votes, confirming their election [14] Business Line Data and Key Metrics Changes - No specific data on business lines or key metrics changes were provided in the meeting records Market Data and Key Metrics Changes - No specific market data or key metrics changes were provided in the meeting records Company Strategy and Development Direction and Industry Competition - The meeting focused on the election of directors and the ratification of the independent auditor, indicating a focus on governance and compliance [12][15] - The approval of executive compensation on an advisory basis suggests a commitment to aligning management incentives with shareholder interests [15] Management's Comments on Operating Environment and Future Outlook - No specific comments from management regarding the operating environment or future outlook were provided in the meeting records Other Important Information - The meeting was conducted virtually, allowing stockholders to participate and vote online [4][3] - The final voting results will be detailed in a current report on Form 8-K to be filed with the SEC within four days [15] Q&A Session Summary - There were no questions submitted during the Q&A session, leading to the conclusion of the annual meeting [16]

Summary of Guardant Health (GH) FY Conference Call - June 09, 2025 Company Overview - **Company**: Guardant Health (GH) - **Industry**: Life Sciences Tools and Diagnostics Key Highlights and Core Points 1. **Strong Business Performance**: The company reported significant growth in the first half of the year, particularly with the G360 therapy selection platform, driven by new features and the smart liquid biopsy platform [3][4] 2. **REVEAL Test Success**: The REVEAL test for colorectal cancer (CRC) surveillance is gaining traction, with increasing volumes and reimbursement developments [4][12] 3. **Breast Cancer Indication**: A second publication in breast cancer was recently released, with plans to submit for Medicare reimbursement [4][10] 4. **Shield Test Updates**: The Shield test has seen a price increase from $9.20 to $14.95, and it has received ADLT status, indicating strong market positioning [4][35] 5. **NCCN Guidelines Impact**: The updated NCCN guidelines recommending testing every three years for Shield are expected to positively impact adoption and coverage [7][8] 6. **Breakthrough Device Designation**: Shield received breakthrough device designation for multi-cancer detection, which may expedite market entry and reimbursement discussions [10][11] 7. **ASCO Conference Insights**: The company presented significant data at ASCO, including the largest MRD study to date, validating the REVEAL test as a decision support tool [12][13] 8. **Competitive Landscape**: Guardant Health maintains a competitive edge with its smart liquid biopsy platform, which offers faster results and higher sensitivity compared to competitors [19][20] 9. **Tissue Test Launch**: The launch of Guardant360 Tissue aims to penetrate the crowded tissue testing market, leveraging the company's established liquid biopsy reputation [24][26] 10. **MRD Test Expansion**: The REVEAL test is gaining traction among patients who are further out from surgery or have inaccessible tissue samples, indicating a strong market opportunity [29][30] 11. **First Mover Advantage**: The company emphasizes the importance of its first mover advantage in the screening market, particularly with the Shield test [33][34] 12. **ASP Growth**: The average selling prices (ASPs) for Guardant360 and REVEAL tests have increased significantly, contributing to revenue growth [39][40] 13. **Path to Profitability**: The company targets breakeven by 2028, with a focus on reducing cash burn and improving gross margins across its product portfolio [47][48] 14. **Long-term Gross Margin Goals**: Guardant Health aims for gross margins of at least 60% across all products, with specific targets for Guardant360 and REVEAL [50][51] Additional Important Insights - **Biopharma Business Success**: The biopharma segment has shown strong growth, with over 80 pharmaceutical companies utilizing Guardant's services [58][59] - **Sales Team Effectiveness**: The company has achieved high effectiveness and perceived utility in its oncology sales team, which is crucial for market penetration [28][62] - **Future Growth Potential**: The company believes that the combination of new product launches, data releases, and market dynamics will drive significant growth in the coming years [64][65]

Core Insights - Tempus AI (TEM) is on track to achieve a significant milestone in its 10th year, projecting a full-year adjusted EBITDA of $5 million, which represents an improvement of approximately $110 million over 2024 [1] - The company narrowed its adjusted EBITDA loss by $27.8 million year over year to negative $16.2 million, indicating effective cost management [1][10] Revenue and Profitability - First-quarter revenues surged by 75.4% year over year, driven by an 89% increase in Genomics, a 31% rise in Oncology testing, and a $63.5 million contribution from Hereditary testing [2] - Gross profit increased at an even higher rate of 99.8% year over year, nearly doubling the growth rate from the previous quarter, supported by gross margin expansion in Genomics and Data and services [2] Competitive Landscape - Compared to older peers like Guardant Health and Myriad Genetics, which are still facing significant annual losses, Tempus is experiencing rapid growth and margin improvements, positioning itself for a promising shift to profitability [3] - Guardant Health reported an adjusted EBITDA loss of $58.5 million for Q1 2025, while Myriad Genetics posted an adjusted EBITDA near breakeven [4][5] Stock Performance - Year to date, Tempus AI shares have increased by 71.8%, significantly outperforming the industry average growth of 22.9% [8][10] - The stock trades at a forward 12-month sales multiple of 7.36X, which is lower than its median of 28.64X but above the industry average of 6.03X [9]

Summary of Guardant Health (GH) 2025 Conference Call Company Overview - **Company**: Guardant Health (GH) - **Industry**: In Vitro Diagnostics (IVD) Key Points and Arguments FDA Breakthrough Designation - Guardant Health received FDA breakthrough designation for its multi-cancer detection test, Shield, which is expected to expedite the path to market and enhance communication with the FDA [3][4] NCCN Recommendation - The National Comprehensive Cancer Network (NCCN) has recommended Shield as a Category 2A screening test for colorectal cancer, which is anticipated to boost adoption among physicians and improve discussions with commercial payers [4][6] Unmet Need in Cancer Screening - There are approximately 50 million unscreened patients, highlighting a significant unmet need in cancer screening. The introduction of Shield is seen as a new choice for patients [6][7] SERENO-six Study - The SERENO-six study, in collaboration with AstraZeneca, is expected to change the paradigm of care in oncology by allowing for adaptive management of patients based on molecular progression [9][10] Volume Growth and Market Expansion - Following the ESR1 approval, Guardant Health experienced a doubling of breast cancer volume, with expectations for similar growth from the new study [11] - The company has launched 11 new applications for its smart liquid biopsy program, indicating a strong pipeline for future growth [12][13] Pricing and ASP Improvement - The average selling price (ASP) for Guardant360 has increased from approximately $2,700 to $3,000-$3,100, with expectations for further increases to $3,200-$3,300 [19][21] - Medicare reimbursement rates have also improved, contributing to the positive pricing environment [20] New Applications and Features - New applications for liquid biopsy include negative prediction for mutations and features for immune checkpoint inhibitors, enhancing the diagnostic capabilities of the tests [22][23] Tissue Test Enhancements - The company has made significant enhancements to its tissue tests, reducing the amount of tissue needed and improving the breadth of genomic testing [26][28] Reveal Product Line - The Reveal product line has shown positive gross margins and is expected to ramp up significantly in the second half of the year, driven by new reimbursement for colorectal cancer surveillance [29][30][31] Future Indications and Market Needs - Guardant Health is making progress on submissions for new indications in breast cancer and immuno-oncology, with expectations for publications and submissions by early next year [32][34] Multi-Cancer Detection and Reimbursement - The company is focused on developing a multi-cancer detection solution, starting with colorectal cancer, and plans to expand reimbursement pathways as the test evolves [60][61] Abu Dhabi Project - Guardant Health is involved in a government-funded population-scale screening program in Abu Dhabi, aiming to improve colorectal cancer screening compliance in the region [63] Additional Important Insights - The company is actively hiring and training sales representatives, aiming to increase its field presence from 100 to over 200 by the end of the year [45][47] - Cost of goods sold (COGS) has decreased significantly, with plans to further reduce costs through automation and workflow efficiencies [49][51] - The company is optimistic about the upcoming Shield 2.0, with expectations for improved analytical performance and potential FDA approval by the end of the year [52][54] This summary encapsulates the key discussions and insights from the Guardant Health conference call, highlighting the company's strategic initiatives, market opportunities, and growth prospects in the IVD industry.

Precision oncology specialist Guardant Health (GH 8.53%) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped almost 9% higher today. This made it quite the outperformer on the exchange, as the bellwether S&P 500 index's gain was a relatively modest 0.6%.A new designationThis morning before market open, Guardant announced that the U.S. Food and Drug Administration (FDA) had granted the healthcare company's Shield multi-cance ...

Core Insights - Guardant Health's stock is experiencing an increase following the FDA's Breakthrough Device designation for its Shield multi-cancer detection test [1] - The Shield MCD test is designed for multi-cancer screening in individuals aged 45 or older at average risk, targeting various cancer types [1] Clinical Validation - At the 2025 ASCO Annual Meeting, Guardant presented data showing the Shield MCD test's high specificity and clinically meaningful sensitivity across multiple tumor types [2] - The test demonstrated 98.6% specificity and 75% sensitivity for detecting bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic cancers, with a cancer signal origin accuracy of 92% [3] NCCN Guidelines Update - The National Comprehensive Cancer Network (NCCN) has included the Shield blood test in its updated colorectal cancer screening guidelines, recommending testing every three years [4] - The NCCN's guideline update references the ECLIPSE study, which showed the Shield test's effectiveness in detecting colorectal cancer with a sensitivity of 83% [5] Stock Performance - Following these developments, Guardant Health's stock price rose by 10.4%, reaching $46.49 [5]